BlinkLab (ASX: BB1): The Penny Stock Quietly Advancing Smartphone-Based Autism Diagnostics
Most penny stocks talk big. BlinkLab is quietly executing on something real and it is doing it inside clinics, not concepts.
BlinkLab is developing a smartphone-based diagnostic platform that uses facial recognition and AI to assess neurodevelopmental conditions. Its first product, Dx1, targets autism detection in children. The company is currently progressing through a US FDA 510(k) clinical trial.
As of the March 2024 quarter, recruitment was underway across multiple trial sites, with 91 children enrolled out of the 100 targeted for the initial phase. The broader study is expected to include up to 1,000 participants.
- IRB and FDA 510(k) study approved and initiated
- 91 of 100 children recruited for first trial phase
- Cash position at 31 March 2024 was $3.1 million
BlinkLab also completed an independent placement of $7.66 million to support its ADHD-focused platform, Dx2, which builds on the same infrastructure as Dx1. The company reported that demand from institutional and sophisticated investors exceeded available capacity, resulting in oversubscription.
Early clinical validation data has shown promising results. Sensitivity was reported at 91 percent and specificity at 85 percent, based on studies referenced in the company’s investor update.
BlinkLab’s mobile testing framework is designed for high scalability and low friction, aligning with the needs of widespread clinical application.
With recruitment already in motion, multiple programs underway, and new capital secured, BlinkLab is positioning itself as a serious contender in the digital diagnostics space.
And it is doing it while most of the market is looking the other way.
Argenica Therapeutics (ASX: AGN): The Penny Stock Quietly Advancing Neuroprotection
Some penny stocks chase headlines. Argenica Therapeutics is focused on clinical progress, patient data and long-term impact.
The company’s lead candidate, ARG-007, is being developed as a neuroprotective treatment for stroke and traumatic brain injury. It is currently being tested in a double-blind, placebo-controlled Phase 2 trial for patients with acute ischaemic stroke. Dosing has already been completed across eight hospitals in Australia, with 92 patients successfully enrolled.
- $12.9 million in cash as of 31 March 2025
- Over $4 million in non-dilutive grant funding secured
- Topline trial data expected in Q3 2025
Early updates confirm that no safety concerns have been identified. The same drug is being tested in traumatic brain injury. In a recent ferret model study, a single dose of ARG-007 reduced axonal damage and inflammation and improved both motor and memory performance.
The company has also launched a preclinical program targeting brain injury in newborns, known as hypoxic ischaemic encephalopathy. This would represent a third application for the same therapy platform.
In the United States, the FDA has requested additional information before greenlighting a local trial. The company is preparing its response. Australian trials continue as planned.
A new US patent was granted for the use of ARG-007 to prevent stroke during high-risk surgeries. The patent is valid until 2034.
Argenica is not chasing speculative attention. It is delivering on a focused clinical path with multiple shots on goal.
And while the market watches larger names, this one is quietly building something that matters.
(Source: Company Announcements)
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
